RESULTS ROUND-UP: Strong US performance boosts Bard; Varian has befuddling Q4
This article was originally published in Clinica
CR Bard had a good third quarter marked by “strong underlying US growth,” according to Jefferies analyst Raj Denhoy. Overall, Q3 sales grew 9% to $830m, $11m higher than analysts had expected. US revenues increased 13% year-on-year to $565.4m, while Bard was also helped by another royalty payment from rival Gore of $38m.